Single-use technologies are becoming widely utilised in the biopharmaceutical industry for the benefit of offering a more flexible, cost-effective approach to cGMP manufacturing. Single-use technologies are utilised in more than 45% of clinical mammalian cell culture processes and about 6% of commercial processes. In this report, Jay Harp and Timothy Korwan at Avantor will discuss four best practices that biopharma companies should consider in developing and managing their single-use supply chain.